Needham Downgrades KalVista Pharmaceuticals to Hold

Benzinga Newsdesk www.benzinga.com Negative 88.5%

Neg 88.5% Neu 0% Pos 0%

Needham analyst Serge Belanger downgrades KalVista Pharmaceuticals (NASDAQ:KALV) from Buy to Hold.

Comments

No comments yet. Be the first!